Skip to content
Research Article Open access CC BY 3.0

Visual Outcome versus Vision Satisfaction after Intravitreal Bevasizumb Injection in Diabetic Retinopathy

Gholamhossein Yaghoobi, Mohammad Ali Yaghoobi, Shima Mirshahi

Ophthalmology Research: An International Journal · pp. 352–360 · Published 27 Jun 2014

10.9734/OR/2014/10095

Abstract

Introduction: Diabetic retinopathy as an important complication of diabetes mellitus is a common cause of blindness in diabetic people. A cure or treatment is not available yet. This study was designed to investigate the effectiveness of the intravitreal injection of Avastin on patient’s visual satisfaction with diabetic retinopathy. Materials and Methods: This study included 30 eyes of thirty diabetic retinopathy patients (mean age: 60.47±8.94 years) showing no recovery with common treatments. After the intravitreal injection of 1.25mg/0.05ml of Avastin, the examination was performed after injection. In this examination, the resolution of neovascularization, clearance of vitreous and visual acuity were evaluated versus visual satisfaction. Results: 60% of patients were women (n=18) and 40% were men (n=12). All patients had type 2 diabetes for a period of 8. 47±5.28 years (range 2-25 years). The observed change was 0.22±0.63 log MAR in the best corrected visual acuity (BCVA) in right eye which was statistically significant (p=0.010). The BCVA in left eye was 0.31±0.74 log mar, also showing significant relation (p=0.020). BCVA Changes did not have a meaningful relationship with age and sex of patients, but these changes were negatively related to duration of diabetes retinopathy in both right and left eyes (p=0/048, p=0/006 respectively). Conclusion: Avastin showed short-term statistically significant visual benefits and also, improvements in ophthalmic pathology in clinical examination versus visual satisfaction, however it was not compatible to ask all of the patient's visual satisfaction. Therefore, further studies will be needed to determine the therapeutic effects of this treatment option.  

Diabetic retinopathy vision satisfaction avastin

References (18)

  1. 1 Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema [DOI]
  2. 2 Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy [DOI]
  3. 3 Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study) [DOI]
  4. 4 A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study) [DOI]
  5. 5 Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema [DOI]
  6. 6 A review of clinical trials of anti-VEGF agents for diabetic retinopathy [DOI]
  7. 7 Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy [DOI]
  8. 8 Anti-VEGF for the Management of Diabetic Macular Edema [DOI]
  9. 9 The impact of metabolic parameters on clinical response to VEGF inhibitors for diabetic macular edema [DOI]
  10. 10 A Prospective Randomized Trial of Intravitreal Bevacizumab or Laser Therapy in the Management of Diabetic Macular Edema (BOLT Study): 12-Month Data: Report 2 [DOI]
  11. 11 Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema: Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up [DOI]
  12. 12 Intravitreal bevacizumab (Avastin®) in proliferative diabetic retinopathy [DOI]
  13. 13 Intravitreal Bevacizumab for Diabetic Macular Edema Associated With Severe Capillary Loss: One-Year Results of a Pilot Study [DOI]
  14. 14 Diabetic Retinopathy: An Update on Treatment [DOI]
  15. 15 Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy.
  16. 16 Intravitreal Bevacizumab (Avastin) in Proliferative Diabetic Retinopathy
  17. 17 Is intravitreal bevacizumab treatment effective in diffuse diabetic macular edema? [DOI]
  18. 18 In vision trial, some researchers would rather see double [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

60

Page views

0

PDF downloads

23

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.